Current Hepatitis Reports

, Volume 3, Issue 1, pp 30–37

Recent peginterferon and ribavirin combination trials

  • Stephanos J. Hadziyannis
  • George V. Papatheodoridis
Article

DOI: 10.1007/s11901-004-0006-9

Cite this article as:
Hadziyannis, S.J. & Papatheodoridis, G.V. Curr hepatitis rep (2004) 3: 30. doi:10.1007/s11901-004-0006-9

Abstract

Peginterferon alpha and ribavirin combination is the recommended first choice therapeutic regimen for chronic hepatitis C. Therapy duration and ribavirin dose are individualized according to the hepatitis C virus genotype. Patients with genotype 1 require 48-week courses with the usual ribavirin doses, whereas 24-week courses with lower ribavirin doses are sufficient for patients with genotype 2/3. In patients with genotype 1, the absence of an early (week 12) virologic response means no chance for sustained response and signals therapy discontinuation.

Copyright information

© Current Science Inc. 2004

Authors and Affiliations

  • Stephanos J. Hadziyannis
    • 1
  • George V. Papatheodoridis
    • 1
  1. 1.Department of Medicine & HepatologyHenry Dunant HospitalAthensGreece

Personalised recommendations